Tango Therapeutics' TNG908 IND For Cancer Study Gets Green Signal By FDA


The FDA has cleared Tango Therapeutics Inc's TNGX Investigational New Drug (IND) application for its lead program, TNG908.

  • TNG908 is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to kill cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion. 
  • MTAP deletions occur in 10% - 15% of all human cancers.
  • Tango expects to initiate a Phase 1/2 trial in 1H of 2022, with preliminary safety and efficacy data expected in 1H of 2023.
  • Enrollment will be limited to patients with confirmed MTAP-deleted tumors. 
  • Related: Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm.
  • The Company is also working on Target 3, an undisclosed synthetic lethal target.
  • In animal studies, Target 3 inhibition, combined with an anti-PD1 antibody, resulted in complete regressions and the induction of immune memory against re-implantation of tumors.
  • Tango expects to advance a development candidate in the first half of 2022 and file an IND in 2023.
  • The Company anticipates advancing a development candidate for their ubiquitin-specific protease 1 (USP1) program in 2H of 2022.
  • Price Action: TNGX shares are down 5.96% at $7.81 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!